NCT01943851 · OUTCOME

Part 1: Number of Participants With Grade Change From Baseline in Clinical Chemistry Parameters

A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies · Source last updated 2024-10-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: Up to 86.9 weeks

What was measured

Blood samples were collected for the analysis of following clinical chemistry parameters: glucose, prothrombin international normalized ratio (Pro. INR), albumin, amylase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, calcium, calcium ionized, cholesterol, creatinine, creatine kinase, lipase, potassium, magnesium, sodium, triglycerides, alkaline phosphatase (ALP). Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Higher grade indicates greater severity. An increase was defined as an increase relative to Baseline. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any grade increase is presented.

Analysis population: All Treated Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in category titles).

Groups in this outcome

Part 1: GSK525762 5 mg QD

Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.

Part 1: GSK525762 10 mg QD

Participants were administered once daily oral dose of 10 mg GSK525762.

Part 1: GSK525762 20 mg QD

Participants were administered once daily oral dose of 20 mg GSK525762.

Part 1: GSK525762 30 mg QD MM

Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.

Part 1: GSK525762 40 mg QD

Participants were administered once daily oral dose of 40 mg GSK525762.

Part 1: GSK525762 40 mg QD MM

Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.

Part 1: GSK525762 60 mg QD AML

Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.

Part 1: GSK525762 60 mg QD NHL

Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.

Part 1: GSK525762 60 mg QD MM

Participants with MM were administered once daily oral dose of 60 mg GSK525762.

Part 1: GSK525762 75 mg QD AML

Participants with AML were administered once daily oral dose of 75 mg GSK525762.

Part 1: GSK525762 80 mg QD

Participants were administered once daily oral dose of 80 mg GSK525762.

Part 1: GSK525762 80 mg QD AML

Participants with AML were administered once daily oral dose of 80 mg GSK525762.

Part 1: GSK525762 80 mg QD NHL

Participants with NHL were administered once daily oral dose of 80 mg GSK525762.

Part 1: GSK525762 100 mg QD AML

Participants with AML were administered once daily oral dose of 100 mg GSK525762.

Part 1: GSK525762 120 mg QD AML

Participants with AML were administered once daily oral dose of 120 mg GSK525762.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Part 1: GSK525762 5 mg QD	1
Part 1: GSK525762 10 mg QD	1
Part 1: GSK525762 20 mg QD	1
Part 1: GSK525762 30 mg QD MM	5
Part 1: GSK525762 40 mg QD	1
Part 1: GSK525762 40 mg QD MM	4
Part 1: GSK525762 60 mg QD AML	8
Part 1: GSK525762 60 mg QD NHL	18
Part 1: GSK525762 60 mg QD MM	3
Part 1: GSK525762 75 mg QD AML	8
Part 1: GSK525762 80 mg QD	1
Part 1: GSK525762 80 mg QD AML	7
Part 1: GSK525762 80 mg QD NHL	7
Part 1: GSK525762 100 mg QD AML	16
Part 1: GSK525762 120 mg QD AML	6

Reported measurements

Glucose, n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,6

Analysis denominator · Participants

Group	Source count
Part 1: GSK525762 5 mg QD	1
Part 1: GSK525762 10 mg QD	1
Part 1: GSK525762 20 mg QD	1
Part 1: GSK525762 30 mg QD MM	5
Part 1: GSK525762 40 mg QD	1
Part 1: GSK525762 40 mg QD MM	4
Part 1: GSK525762 60 mg QD AML	7
Part 1: GSK525762 60 mg QD NHL	18
Part 1: GSK525762 60 mg QD MM	3
Part 1: GSK525762 75 mg QD AML	8
Part 1: GSK525762 80 mg QD	1
Part 1: GSK525762 80 mg QD AML	7
Part 1: GSK525762 80 mg QD NHL	7
Part 1: GSK525762 100 mg QD AML	16
Part 1: GSK525762 120 mg QD AML	6

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: GSK525762 5 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 10 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 20 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 30 mg QD MM	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD MM	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD AML	6	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD NHL	16	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD MM	2	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 75 mg QD AML	8	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD AML	6	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD NHL	6	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 100 mg QD AML	15	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 120 mg QD AML	3	Not reported	Not reported	Not reported	Not reported

Pro.INR, n=0,1,1,5,1,3,4,16,3,4,0,6,5,11,4

Analysis denominator · Participants

Group	Source count
Part 1: GSK525762 5 mg QD	0
Part 1: GSK525762 10 mg QD	1
Part 1: GSK525762 20 mg QD	1
Part 1: GSK525762 30 mg QD MM	5
Part 1: GSK525762 40 mg QD	1
Part 1: GSK525762 40 mg QD MM	3
Part 1: GSK525762 60 mg QD AML	4
Part 1: GSK525762 60 mg QD NHL	16
Part 1: GSK525762 60 mg QD MM	3
Part 1: GSK525762 75 mg QD AML	4
Part 1: GSK525762 80 mg QD	0
Part 1: GSK525762 80 mg QD AML	6
Part 1: GSK525762 80 mg QD NHL	5
Part 1: GSK525762 100 mg QD AML	11
Part 1: GSK525762 120 mg QD AML	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: GSK525762 10 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 20 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 30 mg QD MM	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD AML	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD NHL	10	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 75 mg QD AML	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD AML	4	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD NHL	5	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 100 mg QD AML	8	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 120 mg QD AML	3	Not reported	Not reported	Not reported	Not reported

Albumin, n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,6

Analysis denominator · Participants

Group	Source count
Part 1: GSK525762 5 mg QD	1
Part 1: GSK525762 10 mg QD	1
Part 1: GSK525762 20 mg QD	1
Part 1: GSK525762 30 mg QD MM	5
Part 1: GSK525762 40 mg QD	1
Part 1: GSK525762 40 mg QD MM	4
Part 1: GSK525762 60 mg QD AML	7
Part 1: GSK525762 60 mg QD NHL	18
Part 1: GSK525762 60 mg QD MM	3
Part 1: GSK525762 75 mg QD AML	8
Part 1: GSK525762 80 mg QD	1
Part 1: GSK525762 80 mg QD AML	7
Part 1: GSK525762 80 mg QD NHL	7
Part 1: GSK525762 100 mg QD AML	16
Part 1: GSK525762 120 mg QD AML	6

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: GSK525762 5 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 10 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 20 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 30 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD MM	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD AML	4	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD NHL	7	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 75 mg QD AML	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD AML	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD NHL	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 100 mg QD AML	6	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 120 mg QD AML	1	Not reported	Not reported	Not reported	Not reported

ALT, n=1,1,1,5,1,4,8,18,3,8,1,7,7,15,6

Analysis denominator · Participants

Group	Source count
Part 1: GSK525762 5 mg QD	1
Part 1: GSK525762 10 mg QD	1
Part 1: GSK525762 20 mg QD	1
Part 1: GSK525762 30 mg QD MM	5
Part 1: GSK525762 40 mg QD	1
Part 1: GSK525762 40 mg QD MM	4
Part 1: GSK525762 60 mg QD AML	8
Part 1: GSK525762 60 mg QD NHL	18
Part 1: GSK525762 60 mg QD MM	3
Part 1: GSK525762 75 mg QD AML	8
Part 1: GSK525762 80 mg QD	1
Part 1: GSK525762 80 mg QD AML	7
Part 1: GSK525762 80 mg QD NHL	7
Part 1: GSK525762 100 mg QD AML	15
Part 1: GSK525762 120 mg QD AML	6

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: GSK525762 5 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 10 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 20 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 30 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD AML	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD NHL	4	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 75 mg QD AML	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD AML	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD NHL	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 100 mg QD AML	4	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 120 mg QD AML	0	Not reported	Not reported	Not reported	Not reported

Amylase, n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,5

Analysis denominator · Participants

Group	Source count
Part 1: GSK525762 5 mg QD	1
Part 1: GSK525762 10 mg QD	1
Part 1: GSK525762 20 mg QD	1
Part 1: GSK525762 30 mg QD MM	5
Part 1: GSK525762 40 mg QD	1
Part 1: GSK525762 40 mg QD MM	4
Part 1: GSK525762 60 mg QD AML	7
Part 1: GSK525762 60 mg QD NHL	18
Part 1: GSK525762 60 mg QD MM	3
Part 1: GSK525762 75 mg QD AML	8
Part 1: GSK525762 80 mg QD	1
Part 1: GSK525762 80 mg QD AML	7
Part 1: GSK525762 80 mg QD NHL	7
Part 1: GSK525762 100 mg QD AML	16
Part 1: GSK525762 120 mg QD AML	5

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: GSK525762 5 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 10 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 20 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 30 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD MM	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD AML	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD NHL	5	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD MM	2	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 75 mg QD AML	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD AML	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD NHL	4	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 100 mg QD AML	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 120 mg QD AML	0	Not reported	Not reported	Not reported	Not reported

AST, n=1,1,1,5,1,4,8,18,3,8,1,7,7,16,6

Analysis denominator · Participants

Group	Source count
Part 1: GSK525762 5 mg QD	1
Part 1: GSK525762 10 mg QD	1
Part 1: GSK525762 20 mg QD	1
Part 1: GSK525762 30 mg QD MM	5
Part 1: GSK525762 40 mg QD	1
Part 1: GSK525762 40 mg QD MM	4
Part 1: GSK525762 60 mg QD AML	8
Part 1: GSK525762 60 mg QD NHL	18
Part 1: GSK525762 60 mg QD MM	3
Part 1: GSK525762 75 mg QD AML	8
Part 1: GSK525762 80 mg QD	1
Part 1: GSK525762 80 mg QD AML	7
Part 1: GSK525762 80 mg QD NHL	7
Part 1: GSK525762 100 mg QD AML	16
Part 1: GSK525762 120 mg QD AML	6

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: GSK525762 5 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 10 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 20 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 30 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD MM	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD AML	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD NHL	5	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 75 mg QD AML	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD AML	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD NHL	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 100 mg QD AML	4	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 120 mg QD AML	1	Not reported	Not reported	Not reported	Not reported

Bilirubin, n=1,1,1,5,1,4,8,18,3,8,1,7,7,16,6

Analysis denominator · Participants

Group	Source count
Part 1: GSK525762 5 mg QD	1
Part 1: GSK525762 10 mg QD	1
Part 1: GSK525762 20 mg QD	1
Part 1: GSK525762 30 mg QD MM	5
Part 1: GSK525762 40 mg QD	1
Part 1: GSK525762 40 mg QD MM	4
Part 1: GSK525762 60 mg QD AML	8
Part 1: GSK525762 60 mg QD NHL	18
Part 1: GSK525762 60 mg QD MM	3
Part 1: GSK525762 75 mg QD AML	8
Part 1: GSK525762 80 mg QD	1
Part 1: GSK525762 80 mg QD AML	7
Part 1: GSK525762 80 mg QD NHL	7
Part 1: GSK525762 100 mg QD AML	16
Part 1: GSK525762 120 mg QD AML	6

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: GSK525762 5 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 10 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 20 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 30 mg QD MM	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD AML	6	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD NHL	8	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 75 mg QD AML	7	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD AML	6	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD NHL	5	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 100 mg QD AML	12	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 120 mg QD AML	4	Not reported	Not reported	Not reported	Not reported

Calcium, n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,6

Analysis denominator · Participants

Group	Source count
Part 1: GSK525762 5 mg QD	1
Part 1: GSK525762 10 mg QD	1
Part 1: GSK525762 20 mg QD	1
Part 1: GSK525762 30 mg QD MM	5
Part 1: GSK525762 40 mg QD	1
Part 1: GSK525762 40 mg QD MM	4
Part 1: GSK525762 60 mg QD AML	7
Part 1: GSK525762 60 mg QD NHL	18
Part 1: GSK525762 60 mg QD MM	3
Part 1: GSK525762 75 mg QD AML	8
Part 1: GSK525762 80 mg QD	1
Part 1: GSK525762 80 mg QD AML	7
Part 1: GSK525762 80 mg QD NHL	7
Part 1: GSK525762 100 mg QD AML	16
Part 1: GSK525762 120 mg QD AML	6

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: GSK525762 5 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 10 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 20 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 30 mg QD MM	2	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD AML	5	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD NHL	6	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD MM	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 75 mg QD AML	5	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD AML	4	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD NHL	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 100 mg QD AML	6	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 120 mg QD AML	5	Not reported	Not reported	Not reported	Not reported

Calcium Ionized, n=1,1,1,4,1,4,7,17,3,8,1,7,7,15,6

Analysis denominator · Participants

Group	Source count
Part 1: GSK525762 5 mg QD	1
Part 1: GSK525762 10 mg QD	1
Part 1: GSK525762 20 mg QD	1
Part 1: GSK525762 30 mg QD MM	4
Part 1: GSK525762 40 mg QD	1
Part 1: GSK525762 40 mg QD MM	4
Part 1: GSK525762 60 mg QD AML	7
Part 1: GSK525762 60 mg QD NHL	17
Part 1: GSK525762 60 mg QD MM	3
Part 1: GSK525762 75 mg QD AML	8
Part 1: GSK525762 80 mg QD	1
Part 1: GSK525762 80 mg QD AML	7
Part 1: GSK525762 80 mg QD NHL	7
Part 1: GSK525762 100 mg QD AML	15
Part 1: GSK525762 120 mg QD AML	6

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: GSK525762 5 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 10 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 20 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 30 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD MM	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD AML	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD NHL	2	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD MM	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 75 mg QD AML	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD AML	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD NHL	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 100 mg QD AML	6	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 120 mg QD AML	2	Not reported	Not reported	Not reported	Not reported

Cholesterol,n=1,1,1,4,1,4,3,17,3,6,1,7,6,10,3

Analysis denominator · Participants

Group	Source count
Part 1: GSK525762 5 mg QD	1
Part 1: GSK525762 10 mg QD	1
Part 1: GSK525762 20 mg QD	1
Part 1: GSK525762 30 mg QD MM	4
Part 1: GSK525762 40 mg QD	1
Part 1: GSK525762 40 mg QD MM	4
Part 1: GSK525762 60 mg QD AML	3
Part 1: GSK525762 60 mg QD NHL	17
Part 1: GSK525762 60 mg QD MM	3
Part 1: GSK525762 75 mg QD AML	6
Part 1: GSK525762 80 mg QD	1
Part 1: GSK525762 80 mg QD AML	7
Part 1: GSK525762 80 mg QD NHL	6
Part 1: GSK525762 100 mg QD AML	10
Part 1: GSK525762 120 mg QD AML	3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: GSK525762 5 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 10 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 20 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 30 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD AML	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD NHL	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 75 mg QD AML	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD AML	2	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD NHL	2	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 100 mg QD AML	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 120 mg QD AML	0	Not reported	Not reported	Not reported	Not reported

Creatine Kinase, n=1,1,1,2,1,4,8,18,3,7,1,7,7,16,6

Analysis denominator · Participants

Group	Source count
Part 1: GSK525762 5 mg QD	1
Part 1: GSK525762 10 mg QD	1
Part 1: GSK525762 20 mg QD	1
Part 1: GSK525762 30 mg QD MM	2
Part 1: GSK525762 40 mg QD	1
Part 1: GSK525762 40 mg QD MM	4
Part 1: GSK525762 60 mg QD AML	8
Part 1: GSK525762 60 mg QD NHL	18
Part 1: GSK525762 60 mg QD MM	3
Part 1: GSK525762 75 mg QD AML	7
Part 1: GSK525762 80 mg QD	1
Part 1: GSK525762 80 mg QD AML	7
Part 1: GSK525762 80 mg QD NHL	7
Part 1: GSK525762 100 mg QD AML	16
Part 1: GSK525762 120 mg QD AML	6

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: GSK525762 5 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 10 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 20 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 30 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD AML	2	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD NHL	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 75 mg QD AML	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD AML	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD NHL	2	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 100 mg QD AML	4	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 120 mg QD AML	0	Not reported	Not reported	Not reported	Not reported

Creatinine, n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,6

Analysis denominator · Participants

Group	Source count
Part 1: GSK525762 5 mg QD	1
Part 1: GSK525762 10 mg QD	1
Part 1: GSK525762 20 mg QD	1
Part 1: GSK525762 30 mg QD MM	5
Part 1: GSK525762 40 mg QD	1
Part 1: GSK525762 40 mg QD MM	4
Part 1: GSK525762 60 mg QD AML	7
Part 1: GSK525762 60 mg QD NHL	18
Part 1: GSK525762 60 mg QD MM	3
Part 1: GSK525762 75 mg QD AML	8
Part 1: GSK525762 80 mg QD	1
Part 1: GSK525762 80 mg QD AML	7
Part 1: GSK525762 80 mg QD NHL	7
Part 1: GSK525762 100 mg QD AML	16
Part 1: GSK525762 120 mg QD AML	6

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: GSK525762 5 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 10 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 20 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 30 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD AML	4	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD NHL	5	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 75 mg QD AML	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD AML	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD NHL	2	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 100 mg QD AML	6	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 120 mg QD AML	1	Not reported	Not reported	Not reported	Not reported

Lipase, n=1,1,1,5,1,4,6,18,3,8,1,7,6,15,6

Analysis denominator · Participants

Group	Source count
Part 1: GSK525762 5 mg QD	1
Part 1: GSK525762 10 mg QD	1
Part 1: GSK525762 20 mg QD	1
Part 1: GSK525762 30 mg QD MM	5
Part 1: GSK525762 40 mg QD	1
Part 1: GSK525762 40 mg QD MM	4
Part 1: GSK525762 60 mg QD AML	6
Part 1: GSK525762 60 mg QD NHL	18
Part 1: GSK525762 60 mg QD MM	3
Part 1: GSK525762 75 mg QD AML	8
Part 1: GSK525762 80 mg QD	1
Part 1: GSK525762 80 mg QD AML	7
Part 1: GSK525762 80 mg QD NHL	6
Part 1: GSK525762 100 mg QD AML	15
Part 1: GSK525762 120 mg QD AML	6

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: GSK525762 5 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 10 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 20 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 30 mg QD MM	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD AML	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD NHL	5	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD MM	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 75 mg QD AML	2	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD AML	2	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD NHL	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 100 mg QD AML	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 120 mg QD AML	1	Not reported	Not reported	Not reported	Not reported

Potassium, n=1,1,1,5,1,4,7,18,3,8,1,7,6,16,6

Analysis denominator · Participants

Group	Source count
Part 1: GSK525762 5 mg QD	1
Part 1: GSK525762 10 mg QD	1
Part 1: GSK525762 20 mg QD	1
Part 1: GSK525762 30 mg QD MM	5
Part 1: GSK525762 40 mg QD	1
Part 1: GSK525762 40 mg QD MM	4
Part 1: GSK525762 60 mg QD AML	7
Part 1: GSK525762 60 mg QD NHL	18
Part 1: GSK525762 60 mg QD MM	3
Part 1: GSK525762 75 mg QD AML	8
Part 1: GSK525762 80 mg QD	1
Part 1: GSK525762 80 mg QD AML	7
Part 1: GSK525762 80 mg QD NHL	6
Part 1: GSK525762 100 mg QD AML	16
Part 1: GSK525762 120 mg QD AML	6

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: GSK525762 5 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 10 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 20 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 30 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD MM	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD AML	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD NHL	4	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD MM	2	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 75 mg QD AML	5	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD AML	5	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD NHL	4	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 100 mg QD AML	7	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 120 mg QD AML	3	Not reported	Not reported	Not reported	Not reported

Magnesium,n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,6

Analysis denominator · Participants

Group	Source count
Part 1: GSK525762 5 mg QD	1
Part 1: GSK525762 10 mg QD	1
Part 1: GSK525762 20 mg QD	1
Part 1: GSK525762 30 mg QD MM	5
Part 1: GSK525762 40 mg QD	1
Part 1: GSK525762 40 mg QD MM	4
Part 1: GSK525762 60 mg QD AML	7
Part 1: GSK525762 60 mg QD NHL	18
Part 1: GSK525762 60 mg QD MM	3
Part 1: GSK525762 75 mg QD AML	8
Part 1: GSK525762 80 mg QD	1
Part 1: GSK525762 80 mg QD AML	7
Part 1: GSK525762 80 mg QD NHL	7
Part 1: GSK525762 100 mg QD AML	16
Part 1: GSK525762 120 mg QD AML	6

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: GSK525762 5 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 10 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 20 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 30 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD MM	2	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD AML	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD NHL	4	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD MM	2	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 75 mg QD AML	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD AML	4	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD NHL	5	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 100 mg QD AML	8	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 120 mg QD AML	2	Not reported	Not reported	Not reported	Not reported

Sodium, n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,6

Analysis denominator · Participants

Group	Source count
Part 1: GSK525762 5 mg QD	1
Part 1: GSK525762 10 mg QD	1
Part 1: GSK525762 20 mg QD	1
Part 1: GSK525762 30 mg QD MM	5
Part 1: GSK525762 40 mg QD	1
Part 1: GSK525762 40 mg QD MM	4
Part 1: GSK525762 60 mg QD AML	7
Part 1: GSK525762 60 mg QD NHL	18
Part 1: GSK525762 60 mg QD MM	3
Part 1: GSK525762 75 mg QD AML	8
Part 1: GSK525762 80 mg QD	1
Part 1: GSK525762 80 mg QD AML	7
Part 1: GSK525762 80 mg QD NHL	7
Part 1: GSK525762 100 mg QD AML	16
Part 1: GSK525762 120 mg QD AML	6

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: GSK525762 5 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 10 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 20 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 30 mg QD MM	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD MM	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD AML	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD NHL	6	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 75 mg QD AML	4	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD AML	4	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD NHL	2	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 100 mg QD AML	9	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 120 mg QD AML	3	Not reported	Not reported	Not reported	Not reported

Triglycerides, n=1,1,1,4,1,4,3,17,3,6,1,7,6,10,3

Analysis denominator · Participants

Group	Source count
Part 1: GSK525762 5 mg QD	1
Part 1: GSK525762 10 mg QD	1
Part 1: GSK525762 20 mg QD	1
Part 1: GSK525762 30 mg QD MM	4
Part 1: GSK525762 40 mg QD	1
Part 1: GSK525762 40 mg QD MM	4
Part 1: GSK525762 60 mg QD AML	3
Part 1: GSK525762 60 mg QD NHL	17
Part 1: GSK525762 60 mg QD MM	3
Part 1: GSK525762 75 mg QD AML	6
Part 1: GSK525762 80 mg QD	1
Part 1: GSK525762 80 mg QD AML	7
Part 1: GSK525762 80 mg QD NHL	6
Part 1: GSK525762 100 mg QD AML	10
Part 1: GSK525762 120 mg QD AML	3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: GSK525762 5 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 10 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 20 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 30 mg QD MM	2	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD MM	2	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD AML	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD NHL	4	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 75 mg QD AML	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD AML	5	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD NHL	2	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 100 mg QD AML	8	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 120 mg QD AML	2	Not reported	Not reported	Not reported	Not reported

ALP, n=1,1,1,5,1,4,8,18,3,8,1,7,7,16,6

Analysis denominator · Participants

Group	Source count
Part 1: GSK525762 5 mg QD	1
Part 1: GSK525762 10 mg QD	1
Part 1: GSK525762 20 mg QD	1
Part 1: GSK525762 30 mg QD MM	5
Part 1: GSK525762 40 mg QD	1
Part 1: GSK525762 40 mg QD MM	4
Part 1: GSK525762 60 mg QD AML	8
Part 1: GSK525762 60 mg QD NHL	18
Part 1: GSK525762 60 mg QD MM	3
Part 1: GSK525762 75 mg QD AML	8
Part 1: GSK525762 80 mg QD	1
Part 1: GSK525762 80 mg QD AML	7
Part 1: GSK525762 80 mg QD NHL	7
Part 1: GSK525762 100 mg QD AML	16
Part 1: GSK525762 120 mg QD AML	6

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 1: GSK525762 5 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 10 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 20 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 30 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 40 mg QD MM	2	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD AML	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD NHL	2	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 60 mg QD MM	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 75 mg QD AML	0	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD AML	4	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 80 mg QD NHL	3	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 100 mg QD AML	1	Not reported	Not reported	Not reported	Not reported
Part 1: GSK525762 120 mg QD AML	1	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
1
group Id
OG001
value
0
group Id
OG002
value
1
group Id
OG003
value
3
group Id
OG004
value
1
group Id
OG005
value
3
group Id
OG006
value
6
group Id
OG007
value
16
group Id
OG008
value
2
group Id
OG009
value
8
group Id
OG010
value
1
group Id
OG011
value
6
denoms
counts
group Id
OG000
value
1
group Id
OG001
value
1
group Id
OG002
value
1
group Id
OG003
value
5
group Id
OG004
value
1
group Id
OG005
value
4
group Id
OG006
value
7
group Id
OG007
value
18
group Id
OG008
value
3
group Id
OG009
value
8
group Id
OG010
value
1
group Id
OG011
value
7
units
Participants
title
Glucose, n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,6
categories
measurements
group Id
OG001
value
0
group Id
OG002
value
1
group Id
OG003
value
3
group Id
OG004
value
0
group Id
OG005
value
1
group Id
OG006
value
3
group Id
OG007
value
10
group Id
OG008
value
1
group Id
OG009
value
3
group Id
OG011
value
4
group Id
OG012
value
5
group Id
OG013
value
8
denoms
counts
group Id
OG000
value
0
group Id
OG001
value
1
group Id
OG002
value
1
group Id
OG003
value
5
group Id
OG004
value
1
group Id
OG005
value
3
group Id
OG006
value
4
group Id
OG007
value
16
group Id
OG008
value
3
group Id
OG009
value
4
group Id
OG010
value
0
group Id
OG011
value
6
units
Participants
title
Pro.INR, n=0,1,1,5,1,3,4,16,3,4,0,6,5,11,4
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
0
group Id
OG002
value
1
group Id
OG003
value
1
group Id
OG004
value
1
group Id
OG005
value
0
group Id
OG006
value
4
group Id
OG007
value
7
group Id
OG008
value
1
group Id
OG009
value
3
group Id
OG010
value
1
group Id
OG011
value
3
denoms
counts
group Id
OG000
value
1
group Id
OG001
value
1
group Id
OG002
value
1
group Id
OG003
value
5
group Id
OG004
value
1
group Id
OG005
value
4
group Id
OG006
value
7
group Id
OG007
value
18
group Id
OG008
value
3
group Id
OG009
value
8
group Id
OG010
value
1
group Id
OG011
value
7
units
Participants
title
Albumin, n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,6
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
1
group Id
OG004
value
0
group Id
OG005
value
1
group Id
OG006
value
1
group Id
OG007
value
4
group Id
OG008
value
1
group Id
OG009
value
1
group Id
OG010
value
0
group Id
OG011
value
1
denoms
counts
group Id
OG000
value
1
group Id
OG001
value
1
group Id
OG002
value
1
group Id
OG003
value
5
group Id
OG004
value
1
group Id
OG005
value
4
group Id
OG006
value
8
group Id
OG007
value
18
group Id
OG008
value
3
group Id
OG009
value
8
group Id
OG010
value
1
group Id
OG011
value
7
units
Participants
title
ALT, n=1,1,1,5,1,4,8,18,3,8,1,7,7,15,6
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
1
group Id
OG002
value
0
group Id
OG003
value
1
group Id
OG004
value
1
group Id
OG005
value
0
group Id
OG006
value
0
group Id
OG007
value
5
group Id
OG008
value
2
group Id
OG009
value
0
group Id
OG010
value
0
group Id
OG011
value
3
denoms
counts
group Id
OG000
value
1
group Id
OG001
value
1
group Id
OG002
value
1
group Id
OG003
value
5
group Id
OG004
value
1
group Id
OG005
value
4
group Id
OG006
value
7
group Id
OG007
value
18
group Id
OG008
value
3
group Id
OG009
value
8
group Id
OG010
value
1
group Id
OG011
value
7
units
Participants
title
Amylase, n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,5
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
1
group Id
OG003
value
1
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
1
group Id
OG007
value
5
group Id
OG008
value
1
group Id
OG009
value
0
group Id
OG010
value
0
group Id
OG011
value
3
denoms
counts
group Id
OG000
value
1
group Id
OG001
value
1
group Id
OG002
value
1
group Id
OG003
value
5
group Id
OG004
value
1
group Id
OG005
value
4
group Id
OG006
value
8
group Id
OG007
value
18
group Id
OG008
value
3
group Id
OG009
value
8
group Id
OG010
value
1
group Id
OG011
value
7
units
Participants
title
AST, n=1,1,1,5,1,4,8,18,3,8,1,7,7,16,6
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
0
group Id
OG002
value
1
group Id
OG003
value
0
group Id
OG004
value
1
group Id
OG005
value
1
group Id
OG006
value
6
group Id
OG007
value
8
group Id
OG008
value
1
group Id
OG009
value
7
group Id
OG010
value
1
group Id
OG011
value
6
denoms
counts
group Id
OG000
value
1
group Id
OG001
value
1
group Id
OG002
value
1
group Id
OG003
value
5
group Id
OG004
value
1
group Id
OG005
value
4
group Id
OG006
value
8
group Id
OG007
value
18
group Id
OG008
value
3
group Id
OG009
value
8
group Id
OG010
value
1
group Id
OG011
value
7
units
Participants
title
Bilirubin, n=1,1,1,5,1,4,8,18,3,8,1,7,7,16,6
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
2
group Id
OG004
value
0
group Id
OG005
value
1
group Id
OG006
value
5
group Id
OG007
value
6
group Id
OG008
value
0
group Id
OG009
value
5
group Id
OG010
value
0
group Id
OG011
value
4
denoms
counts
group Id
OG000
value
1
group Id
OG001
value
1
group Id
OG002
value
1
group Id
OG003
value
5
group Id
OG004
value
1
group Id
OG005
value
4
group Id
OG006
value
7
group Id
OG007
value
18
group Id
OG008
value
3
group Id
OG009
value
8
group Id
OG010
value
1
group Id
OG011
value
7
units
Participants
title
Calcium, n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,6
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
0
group Id
OG002
value
1
group Id
OG003
value
1
group Id
OG004
value
1
group Id
OG005
value
3
group Id
OG006
value
1
group Id
OG007
value
2
group Id
OG008
value
0
group Id
OG009
value
3
group Id
OG010
value
0
group Id
OG011
value
3
denoms
counts
group Id
OG000
value
1
group Id
OG001
value
1
group Id
OG002
value
1
group Id
OG003
value
4
group Id
OG004
value
1
group Id
OG005
value
4
group Id
OG006
value
7
group Id
OG007
value
17
group Id
OG008
value
3
group Id
OG009
value
8
group Id
OG010
value
1
group Id
OG011
value
7
units
Participants
title
Calcium Ionized, n=1,1,1,4,1,4,7,17,3,8,1,7,7,15,6
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
1
group Id
OG003
value
1
group Id
OG004
value
0
group Id
OG005
value
1
group Id
OG006
value
0
group Id
OG007
value
1
group Id
OG008
value
1
group Id
OG009
value
1
group Id
OG010
value
1
group Id
OG011
value
2
denoms
counts
group Id
OG000
value
1
group Id
OG001
value
1
group Id
OG002
value
1
group Id
OG003
value
4
group Id
OG004
value
1
group Id
OG005
value
4
group Id
OG006
value
3
group Id
OG007
value
17
group Id
OG008
value
3
group Id
OG009
value
6
group Id
OG010
value
1
group Id
OG011
value
7
units
Participants
title
Cholesterol,n=1,1,1,4,1,4,3,17,3,6,1,7,6,10,3
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
1
group Id
OG004
value
0
group Id
OG005
value
1
group Id
OG006
value
2
group Id
OG007
value
3
group Id
OG008
value
1
group Id
OG009
value
0
group Id
OG010
value
0
group Id
OG011
value
1
denoms
counts
group Id
OG000
value
1
group Id
OG001
value
1
group Id
OG002
value
1
group Id
OG003
value
2
group Id
OG004
value
1
group Id
OG005
value
4
group Id
OG006
value
8
group Id
OG007
value
18
group Id
OG008
value
3
group Id
OG009
value
7
group Id
OG010
value
1
group Id
OG011
value
7
units
Participants
title
Creatine Kinase, n=1,1,1,2,1,4,8,18,3,7,1,7,7,16,6
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
1
group Id
OG004
value
0
group Id
OG005
value
1
group Id
OG006
value
4
group Id
OG007
value
5
group Id
OG008
value
1
group Id
OG009
value
1
group Id
OG010
value
0
group Id
OG011
value
3
denoms
counts
group Id
OG000
value
1
group Id
OG001
value
1
group Id
OG002
value
1
group Id
OG003
value
5
group Id
OG004
value
1
group Id
OG005
value
4
group Id
OG006
value
7
group Id
OG007
value
18
group Id
OG008
value
3
group Id
OG009
value
8
group Id
OG010
value
1
group Id
OG011
value
7
units
Participants
title
Creatinine, n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,6

denoms

counts
group Id
OG000
value
1
group Id
OG001
value
1
group Id
OG002
value
1
group Id
OG003
value
5
group Id
OG004
value
1
group Id
OG005
value
4
group Id
OG006
value
8
group Id
OG007
value
18
group Id
OG008
value
3
group Id
OG009
value
8
group Id
OG010
value
1
group Id
OG011
value
7
units
Participants

description

groups

description
Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.
id
OG000
title
Part 1: GSK525762 5 mg QD
description
Participants were administered once daily oral dose of 10 mg GSK525762.
id
OG001
title
Part 1: GSK525762 10 mg QD
description
Participants were administered once daily oral dose of 20 mg GSK525762.
id
OG002
title
Part 1: GSK525762 20 mg QD
description
Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.
id
OG003
title
Part 1: GSK525762 30 mg QD MM
description
Participants were administered once daily oral dose of 40 mg GSK525762.
id
OG004
title
Part 1: GSK525762 40 mg QD
description
Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.
id
OG005
title
Part 1: GSK525762 40 mg QD MM
description
Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.
id
OG006
title
Part 1: GSK525762 60 mg QD AML
description
Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.
id
OG007
title
Part 1: GSK525762 60 mg QD NHL
description
Participants with MM were administered once daily oral dose of 60 mg GSK525762.
id
OG008
title
Part 1: GSK525762 60 mg QD MM
description
Participants with AML were administered once daily oral dose of 75 mg GSK525762.
id
OG009
title
Part 1: GSK525762 75 mg QD AML
description
Participants were administered once daily oral dose of 80 mg GSK525762.
id
OG010
title
Part 1: GSK525762 80 mg QD
description
Participants with AML were administered once daily oral dose of 80 mg GSK525762.
id
OG011
title
Part 1: GSK525762 80 mg QD AML

param Type

COUNT_OF_PARTICIPANTS

population Description

All Treated Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in category titles).

reporting Status

POSTED

time Frame

Up to 86.9 weeks

title

Part 1: Number of Participants With Grade Change From Baseline in Clinical Chemistry Parameters

type

PRIMARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice